ANN ARBOR, Mich., January 19, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it is entering the new year with the implementation of the most ambitious and advanced genetic engineering initiative ever undertaken by the Company. The focus of this project is to dramatically increase strength and elasticity beyond anything ever seen in the area of recombinant spider silk.

The Company reported that its research and development team has successfully completed the construction phase of the most advanced spider silk gene constructs in Kraig’s history. With this milestone achieved, Kraig Labs has now begun the active execution phase of what represents the next evolution in silkworm gene engineering and recombinant spider silk production.

This initiative, now well underway, represents the largest and most complex silkworm gene-engineering project ever undertaken globally. The program builds upon years of proprietary research and production experience and is designed to further expand the performance, scalability, and commercial potential of the Company’s spider silk technologies.

“This project represents a defining moment for our technology platform,” said Kim Thompson, Founder and CEO of Kraig Labs. “Our team has completed the most sophisticated spider silk gene constructs we have ever developed, and we are now advancing into the next phase, creating new materials that we believe will significantly expand the boundaries of what is possible in spider silk production. I believe this is the most ambitious application of genetic engineering to material science in world history and that this work will eclipse anything else being done in biomimicry or applications of molecular biology to material science.”

The new genetic engineering program is intended to drive continued innovation across the Company’s production pipeline, supporting enhanced fiber performance and future product diversification. Kraig Labs expects this effort to further strengthen its leadership position as it advances toward sustained commercial-scale spider silk manufacturing.

“This initiative reflects the depth of our expertise and our long-term commitment to innovation,” Thompson added. “As we continue to advance commercialization of our current product offerings, we are simultaneously investing in the technologies that will define the next generation of spider silk.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., January 12, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has taken possession of its third silkworm rearing center, completing the core physical infrastructure upgrades, underpinning the Company’s massive recombinant spider silk production scale-up planned for 2026.

This newest facility represents the final major component of the Company’s multi-year production expansion strategy. With three fully operational rearing centers, Kraig Labs will be able to run three simultaneous production cycles, providing both production diversity and the capacity required to meet and exceed one metric ton of finished spider silk per month.

This production scale-up, now well underway, is the culmination of years of development and refinement. Each element of the Company’s expansion, including facility design, staffing, geographic location, operational workflows, and training programs, has been optimized based on lessons learned from prior production campaigns.

The newly acquired facility is the largest single-site rearing center the Company has ever operated. This new facility is designed to support significantly higher throughput while maintaining the operational discipline and biological consistency required for large-scale spider silk manufacturing. This facility is expected to unlock the next level of production capacity as the Company rapidly accelerates spider silk output.

Importantly, this new rearing center has been strategically positioned to leverage the Company’s recently acquired mulberry fields, which will supply the expanded feedstock necessary to support this substantial increase in silkworm and spider silk production. These mulberry resources form a critical foundation of the Company’s vertically integrated production model and are expected to play a key role in enabling continuous, high-volume operations across all of its facilities.

The Company is now bringing this new rearing center online and expects to begin operations later this quarter.

“This milestone represents a critical step forward in our evolution as a world-leading supplier of spider silk,” said Kim Thompson, Kraig Labs Founder and CEO. “With this final rearing center secured and supported by expanded mulberry cultivation, we now have the infrastructure and feedstock capacity in place to support continuous, scalable production at levels that position Kraig Labs to fulfill our vision of commercially scalable and cost-effective spider silk production.”

The Company expects to provide additional updates as the facility is commissioned and fully integrated into its 2026 production campaign.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., January 7, 2026 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”, “Kraig Labs”, or “Kraig’s”), a world leader in spider silk technology*, today announced that it has taken possession of three critical mulberry fields for which it previously secured usage rights. The Company has now integrated this new feedstock capacity directly into the ramp-up of its current spider silk production.

With these fields now dedicated solely to its operational use, Kraig Labs has implemented an aggressive production scale-up slated to dramatically advance spider silk production and prepare silk needed to fulfill outstanding materials requests. Mulberry leaf from these fields is now being incorporated into active silkworm rearing cycles, strengthening the Company’s operations and enabling the deployment of more than 1,000,000 BAM-1 Alpha (“Alpha”) production hybrid eggs now scheduled for release.

“This marks an important operational milestone as we scale production,” said Kim Thompson, Founder and CEO of Kraig Labs. “By taking possession of these mulberry fields and integrating them into our production system, we are reinforcing the infrastructure needed to support continuous large-scale silkworm rearing and sustained spider silk manufacturing.”

The proximity of the mulberry fields to Kraig’s production facilities provides logistical efficiencies while enhancing feedstock consistency and supply security. This integration further supports the Company’s vertically coordinated approach to industrializing recombinant spider silk.

In addition to these fields, dedicated solely to the Company’s use and operations, Kraig Labs can access additional mulberry fields through its collaboration with a key government office in Southeast Asia. This, in turn, allows for rapid growth and expansion, removing fixed capacity constraints.

This development comes as Kraig Labs continues to expand production of its Alpha spider silk hybrids and advances towards sustained commercial output across performance textile and other high-value markets.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Merry Christmas, Happy Hanukkah, and Season’s Greetings to all our Shareholders.

Dear Shareholders

The other morning, I came across an article published on RealClearScience about the Christmas spider. This is a tale from Eastern Europe about a spider who spins a beautiful web in a family’s home on Christmas Eve. The glistening web then transforms to silver, a joy and blessing to the family, the value of which elevates them from poverty to prosperity[1].

I was vaguely aware of this story and had been gifted a small ornamental spider years ago, which is always hanging in my home. Reading that story this morning makes me think about the immediate future of Kraig Biocraft Laboratories and the blessings I believe we are poised to gift to the world over this coming year.

2025 was a year of growth and evolution for Kraig Labs. Together, we’ve achieved significant milestones that have strengthened our Company and positioned us for greater success in 2026.

This year kicked off with a series of operational and scientific breakthroughs that I believe will underpin a new year of growth and advancement across the core pillars of our business, spider silk production, end-market commercialization, and research and development of advanced materials.

Our R&D achievements in 2025 expanded both the breadth and depth of our technology platform. Early in the year, we announced the successful development of a recombinant Darwin Bark Spider silk, demonstrating our ability to engineer and express increasingly complex silk proteins with unique performance characteristics. We quickly followed this up with the creation of a Caddis Fly silk, opening the door to entirely new classes of biomaterials with potential for adhesion and underwater performance.

Our introduction of an advanced gene-splicing technology spurred the rapid pace of these developments. This work ultimately led Kraig Labs to a scientific breakthrough that set the world record, doubling the largest known gene insert in silkworm (opening the door for more advanced materials). Collectively, these advancements strengthen the technological foundation upon which all future new materials at Kraig Labs will be built.

2025 marked a stressful, yet pivotal, year in the evolution of our production operations. This year, we set a production record for advanced spider silk reeling utilizing automated reeling equipment – a key breakthrough needed to achieve multi-ton production. However, we fell short of our ultimate total production target.

In late 2025, we released the new BAM-1 ALPHA hybrid (“ALPHA”) that moved us fully into a true production diapausing hybrid. A huge advancement in production that we had been working on for years. 

The ALPHA hybrid produces the same recombinant spider silk as the original BAM-1.  The difference lies entirely in the background genetics that affect almost every other part of the silkworm, except the transgenic silk sequences.  In other words, ALPHA contains no altered transgenic traits from the original BAM-1.  What differentiates ALPHA from the original BAM-1 is that the parental strains (which both carry the original trans genes) are from a different lineage and are as distinct from the originals as a Golden Retriever is from a Rottweiler. 

The improved background genetics results in a critical 22% boost in silk yield compared to the parental strains. That 22% is very significant for increased production and commercialization. ALPHA also boasts improved reeling efficiency on automated machines, all while maintaining the same strength and materials performance, a game-changer for us in 2026.

To support the increased output of the ALPHA hybrids, we added parallel manufacturing facilities, allowing multiple production streams to operate simultaneously. The operational flexibility, capacity, and resilience of this model were key to our fourth-quarter production breakthrough. We’ve produced more than one million ALPHA eggs, which are ready for deployment to make finished spider silk yarn. These achievements reflect years of selective breeding and targeted design efforts that are now translating into meaningful scale and robustness.

Our accomplishments this year were not made alone. In 2025, we were granted operating licenses by two Southeast Asian countries, providing production security and diversification as we continue to leverage the capabilities of our new production spider silk transgenics. We also signed a strategic multi-year collaboration agreement with a key government agency in Southeast Asia, supporting our production growth and providing key resources, facilities, and land. This agreement was the result of several years of groundwork by our team to secure critical support and resources for our operations and the expansion of spider silk production. As we enter 2026, these collaborations are expanding with the granting of lease rights on additional mulberry gardens to supply our growing production capacity.

The addition of parallel manufacturing facilities and our strategic multi-country licensing expansion further diversified our production base, reduced operational risk, and positioned the Company for sustained, scalable growth across Southeast Asia.

Perhaps most exciting, 2025 marked the beginning of Kraig Labs’ transition from development to commercialization and spider silk sales. This year, we engaged with market leaders in the performance sportswear, sports equipment, and luxury fashion segments. The excitement from these segments to explore applications for our spider silk in their product offerings can now be met with near-term product capacity. In November, we secured our first commercial trial order, an important validation of both our technology and our readiness to serve customers in real-world applications. We believe this is just the first of many orders and opportunities for spider silk.

As we look toward 2026, we do so with growing excitement. The accomplishments of 2025, many of which are not yet reflected in our metrics, have built a rock-solid foundation for the years ahead. Our science is stronger, our production is larger and more resilient, our footprint is expanding, and early-stage commercialization is now underway.

On behalf of the entire Kraig Biocraft Laboratories team, we thank you for your patience, belief, and continued support. We look forward to sharing the next chapter of this journey with you.

From all of us at Kraig Biocraft Laboratories, we wish you a peaceful holiday season and a healthy, prosperous New Year. Warmest holiday greetings and sincere appreciation to you and yours.

With gratitude, resolve, and with the warmest wishes for a Merry Merry Christmas and Happy Hanukkah

Kim K. Thompson
Founder & Chief Executive Officer
On behalf of the entire Kraig Labs family

[1] https://www.zmescience.com/feature-post/culture/culture-society/christmas-spiders/

Breakthrough hybrid line continues to demonstrate superior resilience and scalability as the Company advances major production expansion initiatives

ANN ARBOR, Mich., December 15, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the successful completion of its most recent production cycle, yielding more than one million BAM-1 Alpha hybrid eggs. These eggs are now staged for release over the next quarter and will serve as the next wave of recombinant spider silk production.

This milestone marks another decisive validation of the Company’s strategic transition to this more advanced spider silk line. The BAM-1 Alpha line has delivered greater uniformity and significantly greater resiliency throughout every phase of the production process. These gains directly translate into improved throughput, consistency, and reliability for the Company’s expanding spider silk manufacturing platform.

“The success of BAM-1 Alpha is reshaping our production capabilities,” said Kim Thompson, Founder and CEO of Kraig Labs. “These results reaffirm the power of this hybrid line, and to surpass the one-million-egg mark so quickly is further evidence that we are scaling efficiently, effectively, and in direct alignment with our commercial objectives.”

The rising production capacity enabled by BAM-1 Alpha is also fueling the Company’s accelerated expansion initiatives currently underway in Southeast Asia.

“With each new batch, we are strengthening the backbone of our commercial rollout,” Thompson continued. “The reliability and robustness of BAM-1 Alpha allow us to move forward quickly with confidence as we expand production.”

The Company has developed an aggressive production schedule for the next 6 months based on these exciting results and is already putting that plan into action.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., December 8, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that it has been granted usage rights to a significant block of government-owned mulberry gardens located near its spider silk production operations in Southeast Asia.

These land-use rights, granted to Kraig Labs by a key government agency as part of the Company’s collaborative relationship, will play a central role in Kraig Labs’ ongoing production expansion. The Company has agreed to pay a nominal rent for the use of the mulberry gardens. These mulberry gardens will provide the essential feedstock required to support the scaled-up of recombinant spider silk production. This added capacity will directly support the manufacturing of high-performance spider silk yarns targeted at performance textiles, technical apparel, and luxury fashion markets.

The newly secured acreage will provide a reliable and strategically positioned source of high-quality mulberry leaf, an essential input for maintaining production throughput and improved logistics. This alignment between land access, production capacity, and downstream processing is a key component of Kraig Labs’ strategic expansion blueprint.

Today’s announcement follows closely on the Company’s recently announced order from a leading performance sports apparel brand. Kraig Labs is currently finalizing materials for this customer’s pilot development program, which will utilize the Company’s recombinant spider silk fibers. The addition of these mulberry gardens strengthens Kraig Labs’ ability to meet future commercial demand as it advances toward broader market deployments.

“Access to these mulberry gardens marks another critical step in building an integrated and resilient production ecosystem for our spider silk technologies,” said Kim Thompson, Founder and CEO of Kraig Biocraft Laboratories. “Securing direct access to high-quality mulberry acreage gives us greater control over our supply chain and positions us to accelerate production of our BAM-1 Alpha hybrid spider silk. This collaboration with government stakeholders reflects their confidence in the economic and technological potential of our work.”

As this land is transferred to Kraig Labs’ control, the Company will prepare the gardens for incorporation into its expanding spider silk production pipeline. Additional staffing and operational resources will be deployed as part of the integration process, supporting both near-term production increases and the Company’s strategic vision for large-scale commercialization.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., November 25, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, announces the launch of a key hiring initiative at its production operations in Southeast Asia. This expansion of the Company’s production workforce is driven by rapidly increasing throughput, an expanded operational footprint, and preparations for the opening of its newest production center, now in active development.

The Company is ramping up staffing to support what it expects to be a significant increase in production volumes over the coming quarters. These new team members will play a critical role in supporting the deployment of the Company’s advanced spider silk technologies and modernized sericulture systems across its growing network of facilities.

All incoming production staff will receive specialized training under Dr. Nirmal Kumar, one of the world’s foremost sericulture experts. Training under Dr. Kumar will prepare new hires to support operational growth at Kraig Labs’ newest production center, currently in development, increasing capacity, resilience, and commercial production of its high-performance spider silk.

“This hiring initiative reflects the incredible momentum we are building and the strength of our forward-looking production strategy,” said Kim Thompson, Founder and CEO of Kraig Labs. “As we scale up our next-generation spider silk technology and expand our production footprint, we are focused on assembling a team capable of supporting the high growth trajectory we anticipate. Bringing new staff into the fold and having them train directly with Dr. Kumar ensures that we are building the strongest possible foundation for the future of our operations.”

The Company’s expanded workforce will contribute to Kraig Labs’ increasing production capacity and its readiness to meet both near-term production targets and longer-term commercial opportunities. As construction and development of the new production center takes shape, these newly trained team members will be positioned to support the facility’s launch and help drive the Company’s next major phase of growth.

Kraig Labs expects to continue adding staff and resources as it advances its mission of delivering the world’s first cost-effective, eco-friendly, industrial-scale recombinant spider silk.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

Company to deliver spider silk yarns for elite-tier athletic application

ANN ARBOR, Mich., November 17, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*,  today announced that it is fulfilling an order for spider silk from a globally recognized performance sports apparel brand as part of a confidential pilot development program.

This project will incorporate the Company’s  next-generation recombinant spider silk into a cutting-edge application targeted at the highest tier of performance apparel. While specific project details remain protected, Kraig Labs can confirm that the program is designed for one of the most demanding and innovation-focused segments of the athletic market.

This customer’s market leadership, engineering sophistication, and reputation for excellence in performance apparel made them the ideal choice for this initial pilot engagement. Their market leadership and commitment to innovation is the reason Kraig Labs selected to fulfill this request from among the numerous recent inbound inquiries it received.

The Company is now processing a portion of its recombinant spider silk inventory into yarns tailored to the precise specifications provided by the customer’s development team. Delivery of these specialized materials is expected before the end of the first quarter.

As a focused pilot program, this order calls for a small, purpose-built quantity of spider silk designed explicitly for this highly specialized application. Even at this limited scale, the project provides a powerful platform for demonstrating the performance capabilities and commercial potential of the Company’s specialized spider silk technology within a premier performance environment.

“This collaboration underscores the growing recognition of our material’s potential in high-value, high-performance applications,” said Kim Thompson, Kraig Labs’ Founder and CEO. “We are excited to support this project and a customer whose commitment to innovation aligns with our own. We look forward to showcasing what our spider silk can deliver at the elite level of apparel design and performance.”

Kraig Labs will share additional updates as appropriate and consistent with the confidentiality terms of the agreement.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., November 3, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced that its production operations in Vietnam remain fully secure and uninterrupted following the recent series of typhoons that have impacted parts of Southeast Asia.

Kraig Labs confirmed that its spider silk production facilities and infrastructure sustained no damage or disruption, including its mulberry feedstock supplies, from the severe weather events that caused widespread flooding in lowland regions. The Company’s strategic decision made in 2024 to relocate its operations into the protected highlands has proven to be a highly valuable investment in operational resilience and long-term stability.

“Our hearts go out to the many people and businesses across the region who have suffered loss and devastation from these storms. Kraig Labs will be contributing to the relief and recovery efforts, helping those who have been devastated by these disasters,” said Kim Thompson, Founder and CEO of Kraig Labs. “We are deeply grateful that our facilities and personnel are safe, and we remain fully operational. Our highland infrastructure investments have demonstrated their strength and strategic importance.”

Kraig Labs also confirmed that its former facility in Quang Nam province, which has since been closed, was among the areas affected by flooding. However, all Company equipment, staff, and production assets had been permanently and successfully relocated from that site in September, well ahead of the storms.

In addition to moving its infrastructure and production to the highlands, Kraig Labs has implemented a strategy of maintaining multiple, parallel production facilities. This approach not only supports scalability but also serves as an additional safeguard against potential disruptions from natural disasters or other unforeseen events. By building redundancy and flexibility into its production network, the Company continues to strengthen the foundation for long-term growth and reliability.

“With each step forward, we are building greater resilience into every part of our business,” Thompson continued. “Our investments in infrastructure, redundancy, and strategic location have put Kraig Labs in the strongest position in our history. We are confident these facilities will continue to advance our record-setting spider silk production capacity and deliver these amazing materials to consumer markets eager for innovation and disruption.”

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., October 27, 2025 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), a world leader in spider silk technology*, today announced the promotion of Dr. Xiaoli Zhang to the position of Chief Scientist. This promotion follows a series of groundbreaking scientific achievements under Dr. Zhang’s leadership that are laying the foundation for the next generation of spider silk-based super materials.

Dr. Zhang joined Kraig Labs in October 2024 and was challenged with accelerating the Company’s research program and unlocking new scientific frontiers. Tasked with ambitious and transformative objectives, she not only met but exceeded every milestone in record time, positioning Kraig Labs at the forefront of breakthrough discoveries in advanced fibers and bioengineered materials.

“These achievements are nothing short of revolutionary,” said Kim Thompson, founder and CEO of Kraig Labs. “When Dr. Zhang came on board, we asked her to take on challenges that many believed were impossible. In less than a year, she has led our team to breakthroughs that open the door to entirely new categories of super materials. Her promotion to Chief Scientist reflects both the incredible work she has already done and the even more extraordinary advancements we expect under her continued leadership.”

The innovations driven by Dr. Zhang’s research are now forming the blueprint for a new era of material science, pushing the boundaries of what spider silk can achieve. These advancements promise to redefine performance materials and open new opportunities in higher-margin end markets.

“I am deeply honored by this recognition,” said Dr. Zhang. “The past year has shown us what’s possible when science, vision, and determination come together. What we’ve achieved is just the starting point, we are now poised to pioneer materials that will set entirely new standards for strength, flexibility, and performance. The future for spider silk is brighter than ever.”

With Dr. Zhang leading its research initiatives, Kraig Labs remains firmly positioned as a global leader in spider silk innovation, charting a bold course toward the super materials of tomorrow.

Today’s announcement pairs with the breakthroughs in spider silk production at its operations centers in Southeast Asia, further reinforcing the Company’s leading position in the commercialization of sustainable and cost-effective spider silk.

For the latest updates on Kraig Labs and its pioneering spider silk technologies, visit www.kraiglabs.com.

For details about other recent Kraig Labs advancements, please watch the Company’s investor conference at www.kraiglabs.com/videos or on the Company’s YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270. 

To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news   

* For a description of our historical leadership in this technology, please follow this link  https://www.kraiglabs.com/world-leader/

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, Inc.

(720) 288-8495

ir@KraigLabs.com